Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.

Abstract

1Washington University School of Medicine, St. Louis, MO, USA, 2M. D. Anderson Cancer Center, Houston, TX, USA, 3Mt Sinai Hospital, New York, NY, USA, 4Weill Cornell Medical College, New York, NY, USA, 5University of Chicago Medical Center, Chicago, IL, USA, 6Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA and 7John Theurer… (More)
DOI: 10.3109/10428194.2015.1020801

Topics

1 Figure or Table

Cite this paper

@article{Vij2015SerumFL, title={Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.}, author={Ravi Vij and Michael Wang and Sundar Jagannath and Rub{\'e}n Niesvizky and Andrzej Jakubowiak and Edward Kavalerchik and Mei Huang and David S D Siegel}, journal={Leukemia & lymphoma}, year={2015}, volume={56 10}, pages={2959-61} }